Sugi Predict

Sugi Predict / Compounds / SCHEMBL7787515

SCHEMBL7787515

SCHEMBL7787515

CCN(CC)CCCNC(=O)c1cc(Cl)ccc1Nc1ccc(I)cc1C.Cc1cc(I)ccc1Nc1ccc(Cl)cc1C(=O)NCCCN1CCCCC1.Cc1cc(I)ccc1Nc1ccc(Cl)cc1C(=O)NCCN(C(C)C)C(C)C.Cc1cc(I)ccc1Nc1ccc(Cl)cc1C(=O)NCCN1CCOCC1.Cc1cc(I)ccc1Nc1ccc([N+](=O)[O-])cc1C(=O)NCCN1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPT P10636 4/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ EGFR P00533 1/20 0.37
▸ KLK7 P49862 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7787393 0.85 SMN1; SMN2 (0.44) LMNASMN1; SMN2MAPTALDH1A1KMT2A
SCHEMBL7787331 0.81 CYP1A2 (0.44) CYP2C19ALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL6036040 0.80 MAPT (0.56) LMNASMN1; SMN2MAPTALDH1A1CYP1A2
SCHEMBL6035383 0.79 LMNA (0.48) LMNASMN1; SMN2MAPTALDH1A1MEN1
SCHEMBL7785349 0.79 LMNA (0.44) LMNAMAPTALDH1A1KMT2AKDM4E
SCHEMBL7780236 0.78 MAPT (0.35) LMNASMN1; SMN2MAPTCYP2C19MAOB
SCHEMBL6035633 0.78 LMNA (0.49) LMNASMN1; SMN2MAPTALDH1A1CYP1A2
SCHEMBL6035841 0.78 PRMT5 (0.46) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL6035285 0.77 CYP2C19 (0.61) LMNASMN1; SMN2CYP2C19ALDH1A1MEN1
SCHEMBL6035652 0.77 HTR4 (0.46) CYP2C19ALDH1A1MEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1143957-A3 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-02-27 — — EP disclosed
EP-1143957-A2 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-17 — — EP disclosed
EP-1140067-A1 ANTIVIRAL METHOD USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-10 — — EP disclosed
EP-1140046-A1 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER-LAMBERT COMPANY (US) 2001-10-10 — — EP disclosed
EP-1140062-A2 TREATMENT OF ASTHMA WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-10 — — EP disclosed
EP-1140291-A1 COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR WARNER-LAMBERT COMPANY LLC (US) 2001-10-10 — — EP disclosed
WO-2000035435-A9 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER LAMBERT CO (US) 2001-03-22 — — WO disclosed
WO-2000037141-A9 COMBINATION CHEMOTHERAPY WARNER LAMBERT CO (US) 2000-12-07 — — WO disclosed
WO-2000040237-A1 ANTIVIRAL METHOD USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-13 — — WO disclosed
WO-2000040235-A2 TREATMENT OF ASTHMA WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-13 — — WO disclosed
WO-2000037141-A1 COMBINATION CHEMOTHERAPY WARNER-LAMBERT COMPANY (US) 2000-06-29 — — WO disclosed
WO-2000035435-A1 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER-LAMBERT COMPANY (US) 2000-06-22 — — WO disclosed
WO-2000035436-A2 TREATMENT OF ARTHRITIS WITH MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-06-22 — — WO disclosed